A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with `Systemic Sclerosis associated Interstitial Lung Disease'(SSc-ILD).

Administered By

Contributors

Start/End

  • August 15, 2016 - August 14, 2019